Carfilzomib, Belinostat, NHL, Clinical Trials, TCLL

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

This study is currently recruiting participants.

This research study is evaluating a drug called carfilzomib used in combination with another drug called belinostat with participants who have relapsed or refractory non-Hodgkin lymphoma (NHL).

Study Type:  Interventional

Study Design:  

Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study

Conditions:  

Non-Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Peripheral T-cell Lymphoma

Interventions:  

Drug: Carfilzomib
Drug: Belinostat

Phase:  Phase 1

External Link:  https://clinicaltrials.gov/ct2/show/NCT02142530